• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

抗原密度和免疫抑制因子对抗体融合蛋白和双特异性抗体介导的 T 细胞反应的肿瘤靶向共刺激的影响。

Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.

机构信息

Institute of Cell Biology and Immunology, University of Stuttgart, Allmandring 31, 70569, Stuttgart, Germany.

出版信息

Cancer Immunol Immunother. 2020 Nov;69(11):2291-2303. doi: 10.1007/s00262-020-02624-6. Epub 2020 Jun 5.

DOI:10.1007/s00262-020-02624-6
PMID:32504247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7568714/
Abstract

Target expression heterogeneity and the presence of an immunosuppressive microenvironment can hamper severely the efficiency of immunotherapeutic approaches. We have analyzed the potential to encounter and overcome such conditions by a combinatory two-target approach involving a bispecific antibody retargeting T cells to tumor cells and tumor-directed antibody-fusion proteins with costimulatory members of the B7 and TNF superfamily. Targeting the tumor-associated antigens EpCAM and EGFR with the bispecific antibody and costimulatory fusion proteins, respectively, we analyzed the impact of target expression and the influence of the immunosuppressive factors IDO, IL-10, TGF-β, PD-1 and CTLA-4 on the targeting-mediated stimulation of T cells. Here, suboptimal activity of the bispecific antibody at diverse EpCAM expression levels could be effectively enhanced by targeting-mediated costimulation by B7.1, 4-1BBL and OX40L in a broad range of EGFR expression levels. Furthermore, the benefit of combined costimulation by B7.1/4-1BBL and 4-1BBL/OX40L was demonstrated. In addition, the expression of immunosuppressive factors was shown in all co-culture settings, where blocking of prominent factors led to synergistic effects with combined costimulation. Thus, targeting-mediated costimulation showed general promise for a broad application covering diverse target expression levels, with the option for further selective enhancement by the identification and blockade of main immunosuppressive factors of the particular tumor environment.

摘要

靶向表达异质性和免疫抑制微环境的存在可能严重阻碍免疫治疗方法的效率。我们通过一种组合的双靶点方法分析了遇到和克服这种情况的潜力,该方法涉及将双特异性抗体重新靶向肿瘤细胞的 T 细胞,以及具有 B7 和 TNF 超家族共刺激成员的肿瘤定向抗体融合蛋白。我们分别用双特异性抗体和共刺激融合蛋白靶向肿瘤相关抗原 EpCAM 和 EGFR,分析了靶标表达和免疫抑制因子 IDO、IL-10、TGF-β、PD-1 和 CTLA-4 对 T 细胞靶向介导刺激的影响。在这里,在广泛的 EGFR 表达水平下,双特异性抗体在不同 EpCAM 表达水平下的亚最佳活性可以通过 B7.1、4-1BBL 和 OX40L 的靶向介导共刺激有效增强。此外,还证明了 B7.1/4-1BBL 和 4-1BBL/OX40L 的联合共刺激的益处。此外,在所有共培养设置中均检测到免疫抑制因子的表达,其中阻断主要因子导致与联合共刺激产生协同作用。因此,靶向介导的共刺激具有广泛应用的广阔前景,涵盖了广泛的靶标表达水平,并可通过鉴定和阻断特定肿瘤环境中的主要免疫抑制因子进行进一步的选择性增强。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/1e2d7742f85f/262_2020_2624_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/155da1f53659/262_2020_2624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/9555a8de5066/262_2020_2624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/500810284d6d/262_2020_2624_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/71c41efa50ad/262_2020_2624_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/f6a8228ca728/262_2020_2624_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/1e2d7742f85f/262_2020_2624_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/155da1f53659/262_2020_2624_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/9555a8de5066/262_2020_2624_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/500810284d6d/262_2020_2624_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/71c41efa50ad/262_2020_2624_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/f6a8228ca728/262_2020_2624_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/55af/11027697/1e2d7742f85f/262_2020_2624_Fig6_HTML.jpg

相似文献

1
Influence of antigen density and immunosuppressive factors on tumor-targeted costimulation with antibody-fusion proteins and bispecific antibody-mediated T cell response.抗原密度和免疫抑制因子对抗体融合蛋白和双特异性抗体介导的 T 细胞反应的肿瘤靶向共刺激的影响。
Cancer Immunol Immunother. 2020 Nov;69(11):2291-2303. doi: 10.1007/s00262-020-02624-6. Epub 2020 Jun 5.
2
Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.双特异性抗体与共刺激抗体 - 配体融合蛋白联合用于靶向癌症免疫治疗。
J Immunother. 2012 Jun;35(5):418-29. doi: 10.1097/CJI.0b013e3182594387.
3
Tumor-targeted costimulation with antibody-fusion proteins improves bispecific antibody-mediated immune response in presence of immunosuppressive factors.使用抗体融合蛋白进行肿瘤靶向共刺激可在存在免疫抑制因子的情况下改善双特异性抗体介导的免疫反应。
Oncoimmunology. 2017 Aug 17;6(12):e1361594. doi: 10.1080/2162402X.2017.1361594. eCollection 2017.
4
Co-Stimulatory Bispecific Antibodies Induce Enhanced T Cell Activation and Tumor Cell Killing in Breast Cancer Models.共刺激双特异性抗体在乳腺癌模型中诱导增强的 T 细胞激活和肿瘤细胞杀伤。
Front Immunol. 2021 Aug 16;12:719116. doi: 10.3389/fimmu.2021.719116. eCollection 2021.
5
Evaluating combinations of costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy.评估靶向癌症免疫疗法的共刺激抗体 - 配体融合蛋白组合。
Cancer Immunol Immunother. 2013 Aug;62(8):1369-80. doi: 10.1007/s00262-013-1441-7. Epub 2013 May 30.
6
A novel antibody-4-1BBL fusion protein for targeted costimulation in cancer immunotherapy.一种用于癌症免疫治疗中靶向共刺激的新型抗体-4-1BBL融合蛋白。
J Immunother. 2008 Oct;31(8):714-22. doi: 10.1097/CJI.0b013e31818353e9.
7
A novel bispecific tetravalent antibody fusion protein to target costimulatory activity for T-cell activation to tumor cells overexpressing ErbB2/HER2.一种新型双特异性四价抗体融合蛋白,用于靶向共刺激活性,以激活针对过表达ErbB2/HER2的肿瘤细胞的T细胞。
J Mol Biol. 2005 Mar 11;346(5):1299-311. doi: 10.1016/j.jmb.2004.12.052. Epub 2005 Jan 22.
8
Impact of Diverse Immune Evasion Mechanisms of Cancer Cells on T Cells Engaged by EpCAM/CD3-Bispecific Antibody Construct AMG 110.癌细胞多种免疫逃逸机制对EpCAM/CD3双特异性抗体构建体AMG 110所激活的T细胞的影响
PLoS One. 2015 Oct 28;10(10):e0141669. doi: 10.1371/journal.pone.0141669. eCollection 2015.
9
Minimal costimulatory requirements for T cell priming and TH1 differentiation: activation of naive human T lymphocytes by tumor cells armed with bifunctional antibody constructs.T细胞致敏和TH1分化的最低共刺激要求:用双功能抗体构建体武装的肿瘤细胞激活人幼稚T淋巴细胞
Cancer Immun. 2001 Nov 12;1:10.
10
Carcinoembryonic antigen (CEA)-specific T-cell activation in colon carcinoma induced by anti-CD3 x anti-CEA bispecific diabodies and B7 x anti-CEA bispecific fusion proteins.抗CD3×抗癌胚抗原双特异性双抗体和B7×抗癌胚抗原双特异性融合蛋白诱导结肠癌中癌胚抗原(CEA)特异性T细胞活化
Cancer Res. 1999 Jun 15;59(12):2909-16.

引用本文的文献

1
Role of adhesion molecules in cancer and targeted therapy.黏附分子在癌症和靶向治疗中的作用。
Sci China Life Sci. 2024 May;67(5):940-957. doi: 10.1007/s11427-023-2417-3. Epub 2024 Jan 3.
2
Targeting Co-Stimulatory Receptors of the TNF Superfamily for Cancer Immunotherapy.针对 TNF 超家族共刺激受体的癌症免疫疗法。
BioDrugs. 2023 Jan;37(1):21-33. doi: 10.1007/s40259-022-00573-3. Epub 2022 Dec 26.
3
Natural killer cells: a promising immunotherapy for cancer.自然杀伤细胞:癌症有前途的免疫疗法。

本文引用的文献

1
A class of costimulatory CD28-bispecific antibodies that enhance the antitumor activity of CD3-bispecific antibodies.一类共刺激 CD28 双特异性抗体,可增强 CD3 双特异性抗体的抗肿瘤活性。
Sci Transl Med. 2020 Jan 8;12(525). doi: 10.1126/scitranslmed.aaw7888.
2
T Cell-Activating Bispecific Antibodies in Cancer Therapy.T 细胞激活双特异性抗体在癌症治疗中的应用。
J Immunol. 2019 Aug 1;203(3):585-592. doi: 10.4049/jimmunol.1900496.
3
Possible Biomarkers for Cancer Immunotherapy.癌症免疫治疗的潜在生物标志物。
J Transl Med. 2022 May 23;20(1):240. doi: 10.1186/s12967-022-03437-0.
Cancers (Basel). 2019 Jul 3;11(7):935. doi: 10.3390/cancers11070935.
4
Tumor-targeted 4-1BB agonists for combination with T cell bispecific antibodies as off-the-shelf therapy.肿瘤靶向 4-1BB 激动剂与 T 细胞双特异性抗体联合作为现货治疗。
Sci Transl Med. 2019 Jun 12;11(496). doi: 10.1126/scitranslmed.aav5989.
5
Tumor-Localized Costimulatory T-Cell Engagement by the 4-1BB/HER2 Bispecific Antibody-Anticalin Fusion PRS-343.PRS-343:一种 4-1BB/HER2 双特异性抗体-抗钙黏蛋白融合物,可激活肿瘤局部的共刺激 T 细胞。
Clin Cancer Res. 2019 Oct 1;25(19):5878-5889. doi: 10.1158/1078-0432.CCR-18-3654. Epub 2019 May 28.
6
CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids.CEA 表达异质性和可塑性使患者来源的结直肠癌细胞类器官对 CEA 靶向双特异性免疫治疗抗体 cibisatamab(CEA-TCB)产生耐药性。
J Immunother Cancer. 2019 Apr 15;7(1):101. doi: 10.1186/s40425-019-0575-3.
7
Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.联合CD28和4-1BB共刺激增强亲和力优化的嵌合抗原受体工程化T细胞。
Clin Cancer Res. 2019 Jul 1;25(13):4014-4025. doi: 10.1158/1078-0432.CCR-18-2559. Epub 2019 Apr 12.
8
TGFβ Blockade Enhances Radiotherapy Abscopal Efficacy Effects in Combination with Anti-PD1 and Anti-CD137 Immunostimulatory Monoclonal Antibodies.TGFβ 阻断增强了与抗 PD1 和抗 CD137 免疫刺激单克隆抗体联合使用的放射治疗远隔效应。
Mol Cancer Ther. 2019 Mar;18(3):621-631. doi: 10.1158/1535-7163.MCT-18-0558. Epub 2019 Jan 25.
9
M7824: A promising new strategy to combat cancer immune evasion.M7824:一种对抗癌症免疫逃逸的有前景的新策略。
Oncoscience. 2018 Aug 22;5(11-12):269-270. doi: 10.18632/oncoscience.451. eCollection 2018 Nov.
10
CD73 expression on effector T cells sustained by TGF-β facilitates tumor resistance to anti-4-1BB/CD137 therapy.TGF-β 维持的效应 T 细胞表面 CD73 的表达促进了肿瘤对抗 4-1BB/CD137 治疗的耐药性。
Nat Commun. 2019 Jan 11;10(1):150. doi: 10.1038/s41467-018-08123-8.